Organisation paid for research Program year 2025 Source: CMS Open Payments

The Iowa Clinic PC Dermatology

Neither a doctor nor a teaching hospital

Research payments

$1,065,962

248 payments

Through program year 2025, The Iowa Clinic PC Dermatology is reported as receiving $1,065,962 in research payments, across 248 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $77,979 7
2024 Research $465,758 28
2023 Research $334,774 196
2022 Research $187,450 17

Breakdown

Who paid Research payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $978,821 63 payments
  2. Alnylam Pharmaceuticals Inc. $87,141 185 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $486,025 25 payments
  2. A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $251,758 23 payments
  3. A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T $241,038 15 payments
  4. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $87,141 185 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record